Infliximab: Efficacy in psoriasis.

Simple item page
dc.contributor.authorArsiwala, Shehnaz
dc.date.accessioned2013-07-25T09:45:14Z
dc.date.available2013-07-25T09:45:14Z
dc.date.issued2013-07
dc.description.abstractModerate to severe psoriasis often needs to be addressed with standard disease modifying therapies such as methotrexate, cyclosporine, acitretin or ultraviolet radiation, which have their potential benefits and limitations. The tumor necrosis factor-alpha (TNF-α) is elevated in psoriatic plaques compared to non lesional skin as well as in the plasma of patients with moderate to severe psoriasis. Infliximab, a TNF-α blocker, has been recommended for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to these therapies or who cannot tolerate them. Its specific action on the bound and membrane forms of the pro-inflammatory cytokine TNF-α has made it the molecule of choice for obtaining quicker and longer remission in recalcitrant cases. However, the widespread use of infliximab in the Indian subcontinent is limited by its cost. This article reviews the international guidelines for use of infliximab, its dosage patterns, and efficacy in chronic plaque psoriasis, nail psoriasis, erythrodermic psoriasis, and pustular psoriasis as well as Indian experience.en_US
dc.identifier.citationArsiwala Shehnaz. Infliximab: Efficacy in psoriasis. Indian Journal of Dermatology, Venereology and Leprology. 2013 July; 79 Suppl(): S25-34.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/147529
dc.language.isoenen_US
dc.source.urihttps://www.ijdvl.com/article.asp?issn=0378-6323;year=2013;volume=79;issue=7;spage=25;epage=34;aulast=Arsiwalaen_US
dc.subjectInfliximaben_US
dc.subjectpsoriasisen_US
dc.subjecttumor necrosis factor–αen_US
dc.subject.meshAntibodies, Monoclonal --administration & dosage
dc.subject.meshAntibodies, Monoclonal --therapeutic use
dc.subject.meshAsia
dc.subject.meshDermatologic Agents --administration & dosage
dc.subject.meshDermatologic Agents --therapeutic use
dc.subject.meshDisease Progression
dc.subject.meshGuidelines as Topic
dc.subject.meshHumans
dc.subject.meshPsoriasis --drug therapy
dc.subject.meshTumor Necrosis Factor-alpha --antagonists & inhibitors
dc.titleInfliximab: Efficacy in psoriasis.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijdvl2013v79n7ps25.pdf
Size:
832.66 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Dermatology, Venereology and Leprology